Source: FDA, National Drug Code (US) Revision Year: 2020
MYAMBUTOL is indicated for the treatment of pulmonary tuberculosis. It should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. Selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in-vitro susceptibility studies. In patients who have not received previous antituberculous therapy, ie, initial treatment, the most frequently used regimens have been the following:
MYAMBUTOL plus isoniazid
MYAMBUTOL plus isoniazid plus streptomycin.
In patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. Consequently, in such retreatment patients, MYAMBUTOL should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in-vitro studies. Antituberculous drugs used with MYAMBUTOL have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. Isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. Alternating drug regimens have also been utilized.
MYAMBUTOL should not be used alone, in initial treatment or in retreatment. MYAMBUTOL should be administered on a once every 24-hour basis only. Absorption is not significantly altered by administration with food. Therapy, in general, should be continued until bacteriological conversion has become permanent and maximal clinical improvement has occurred.
MYAMBUTOL is not recommended for use in pediatric patients under thirteen years of age since safe conditions for use have not been established.
In patients who have not received previous antituberculous therapy, administer MYAMBUTOL 15 mg/kg (7 mg/lb) of body weight, as a single oral dose once every 24 hours. In the more recent studies, isoniazid has been administered concurrently in a single, daily, oral dose.
In patients who have received previous antituberculous therapy, administer MYAMBUTOL 25 mg/kg (11 mg/lb) of body weight, as a single oral dose once every 24 hours. Concurrently administer at least one other antituberculous drug to which the organisms have been demonstrated to be susceptible by appropriate in-vitro tests. Suitable drugs usually consist of those not previously used in the treatment of the patient. After 60 days of MYAMBUTOL administration, decrease the dose to 15 mg/kg (7mg/lb) of body weight, and administer as a single oral dose once every 24 hours.
During the period when a patient is on a daily dose of 25 mg/kg, monthly eye examinations are advised.
See Table for easy selection of proper weight-dose tablet(s).
Weight-Dose Table:
| 15 mg/kg (7 mg/lb) Schedule | ||
|---|---|---|
| Weight Range | Daily Dose | |
| Pounds | Kilograms | In mg |
| Under 85 lbs. | Under 37 kg | 500 |
| 85-94.5 | 37–43 | 600 |
| 95-109.5 | 43–50 | 700 |
| 110-124.5 | 50–57 | 800 |
| 125-139.5 | 57–64 | 900 |
| 140-154.5 | 64–71 | 1000 |
| 155-169.5 | 71–79 | 1100 |
| 170-184.5 | 79–84 | 1200 |
| 185-199.5 | 84–90 | 1300 |
| 200-214.5 | 90–97 | 1400 |
| 215 and Over | Over 97 | 1500 |
| 25 mg/kg (11 mg/lb) Schedule | ||
| Under 85 lbs. | Under 38 kg | 900 |
| 85-92.5 | 38-42 | 1000 |
| 93-101.5 | 42-45.5 | 1100 |
| 102-109.5 | 45.5–50 | 1200 |
| 110-118.5 | 50–54 | 1300 |
| 119-128.5 | 54–58 | 1400 |
| 129-136.5 | 58–62 | 1500 |
| 137-146.5 | 62–67 | 1600 |
| 147-155.5 | 67–71 | 1700 |
| 156-164.5 | 71–75 | 1800 |
| 165-173.5 | 75–79 | 1900 |
| 174-182.5 | 79–83 | 2000 |
| 183-191.5 | 83–87 | 2100 |
| 192-199.5 | 87–91 | 2200 |
| 200-209.5 | 91–95 | 2300 |
| 210-218.5 | 95–99 | 2400 |
| 219 and Over | Over 99 | 2500 |
Store at controlled room temperature 20° to 25°C (68° to 77°F).
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
